Primary Therapeutic Role: Managing Overactive Bladder (OAB)

Proverine is commonly used across therapeutic domains where additional symptomatic support is needed for patients diagnosed with Overactive Bladder (OAB) syndrome, a condition generally characterized by periods of heightened symptoms. The medication is applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used to help with easing the overall symptom burden in adults and relevant patient groups, including those with neurogenic bladder dysfunction. The primary symptoms addressed include urinary urgency, abnormally increased daytime frequency, and frequent nocturnal voiding (Nocturia).

“The goal is to provide supportive relief when symptoms interfere with routine activities.”

Functional Benefit: Continence and Stability

This medication is applied in addressing symptom clusters that may become intense or disruptive. By addressing these symptoms linked to organ-specific functional stress, Proverine contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort. For patients experiencing involuntary leakage of urine associated with a sudden, compelling desire to void (urge incontinence), Proverine may assist with managing symptoms that create noticeable functional strain. This may provide supportive relief, helping patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Disruptive Urinary Urgency

Regulatory References

1. NIH-affiliated Clinical Review Report

Who Can and Cannot Use Proverine (Medroxyprogesterone Acetate)

The eligibility for Proverine is strictly defined by regulatory bodies and centers on absolute contraindications and specific patient limitations. It is contraindicated and must not be used by individuals with:

• Known or suspected pregnancy. Proverine is classified as posing a risk to the fetus.
• Active or history of thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke).
• Known, suspected, or history of breast cancer or other hormone-dependent malignancies.
• Severe liver impairment or active liver disease.
• Undiagnosed abnormal genital bleeding.

Age and Special Population Restrictions

Use in the pediatric population (children) is generally not established and not indicated. In adolescents receiving the drug for certain indications, long-term use (e.g., over two years) is restricted due to the documented risk of bone mineral density loss.

Patients with cardiac or renal impairment require careful observation during use due to the drug’s potential to cause fluid retention. Use for the prevention of dementia in women 65 years of age or older is not recommended.

Interactions with other medicines and products

Proverine (medroxyprogesterone acetate) may interact with other medicinal products and substances, primarily due to its metabolism through the liver enzyme system. These interactions can affect the concentration of Proverine in the body, potentially altering its effect.

Pharmacokinetic Interactions

Proverine is metabolized primarily by the CYP3A4 enzyme in the liver. Official regulatory information highlights the following categories of interactions:

Interacting Product Category	Effect on Proverine Concentrations	Example Substances
CYP3A4 Inducers	Expected to Decrease	Aminoglutethimide, Carbamazepine, Rifampin, St. John's wort
CYP3A4 Inhibitors	Expected to Increase	Ketoconazole, Itraconazole, Ritonavir

Co-administration with strong CYP3A4 inducers should be avoided as it may significantly reduce Proverine levels, potentially compromising efficacy. The specific medicine Aminoglutethimide is documented to significantly depress Proverine serum concentrations.

Other Documented Interactions

• Food Interaction: Taking the oral tablet with food increases its overall bioavailability (exposure) and maximum concentration, which is a documented pharmacokinetic effect.
• Pharmacodynamic Interactions: Caution is advised with drugs that can reduce bone mass (such as corticosteroids and anticonvulsants), as Proverine may already affect bone mineral density.
• Population Notes: Patients with diabetes must be carefully observed, as Proverine may decrease glucose tolerance.

Proverine (medroxyprogesterone acetate) functions as a synthetic progestin and primarily exerts its cellular effects through agonism of the nuclear progesterone receptor (PR).

Upon binding, Proverine induces a conformational change in the PR, enabling the complex to translocate to the nucleus and interact with specific Hormone Response Elements (HREs) on target DNA. This genomic mechanism modulates the transcription of various genes, resulting in altered cellular protein synthesis. In the reproductive axis, Proverine acts on the hypothalamus and pituitary gland to exert an antigonadotropic effect. This action involves the suppression of Gonadotropin-Releasing Hormone (GnRH) secretion and a resultant decrease in the pulsatile release of pituitary Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). The systemic consequence of this suppression is the inhibition of ovarian follicular maturation. The drug also induces a morphological transformation of the proliferative endometrium into a secretory phase and increases the viscosity of cervical mucus, altering the local environment of the lower reproductive tract. Proverine also exhibits a binding affinity for the glucocorticoid receptor (GR), acting as a partial agonist to modulate glucocorticoid-responsive pathways.

Official Administration and Dosage Guidelines

Proverine (propiverine hydrochloride) is administered exclusively via the oral route, with specific dosing protocols based on the formulation. The dosage regimen for adults depends on the formulation, which includes Immediate-Release (IR) tablets (10 mg or 15 mg) and Modified-Release (MR) capsules (30 mg or 45 mg).

Formulation and Strength	Standard Adult Dosing (Max 45 mg daily)	Frequency
MR Capsules (30 mg, 45 mg)	30 mg or 45 mg	Once daily
IR Tablets (15 mg)	15 mg once or twice daily, up to 15 mg three times daily	Multiple times daily

Procedural Use and Special Constraints

The administration of Proverine is governed by specific procedural and population-based rules. The MR capsules must be swallowed whole and not crushed or chewed to ensure the integrity of the modified-release system. For some IR formulations, instructions specify taking the tablets after a meal.

Population-Specific Dose Limits

• Older Adults: Generally, no specific dose adjustment is required for the geriatric population.
• Renal Impairment: The maximum daily dose is 30 mg for patients with severe renal impairment (creatinine clearance < 30 ml/min). The 45 mg MR capsule is not recommended in this group.
• Hepatic Impairment: Use is not recommended in patients with moderately or severely impaired hepatic function.
• Missed Dose: In the event of a missed dose, the common protocol is to skip the missed dose if it is almost time for the next scheduled dose, and never take two doses at once.

This framework defines the standardized approach to administering the medicine.

Research Evidence / Overview of Studies for Proverine

The research evidence available for Proverine is primarily based on clinical trials and observational studies that have explored the compound's application in conditions characterized by fluctuating or episodic manifestations of urinary dysfunction. This summary focuses on the types of studies conducted and what their findings indicate, without offering any clinical advice or interpretation.

---

Evidence from Trials for Overactive Bladder (OAB) Syndrome

Proverine was studied for the management of symptoms associated with Overactive Bladder (OAB) syndrome. The clinical evidence base centered on short-term randomized, double-blind trials (RCTs), which included both placebo-controlled and active-comparator designs. Researchers designed these studies to measure outcomes related to physical discomfort and functional imbalance, such as the daily frequency of voiding and the severity of urgency. Patient-reported outcomes describing perceived discomfort were also important measures in these research contexts.

Studies conducted during periods of increased symptom activity examined change in the number of daily voiding frequency and incontinence episodes. When Proverine was evaluated in active-comparator trials, the findings described patterns related to measured outcomes that were assessed in the research. The research exploring short-term symptom changes has limited information for long-term outcomes regarding longer use. Comparative evidence is lacking against all currently available treatments.

---

Research Evidence for Neurogenic Detrusor Overactivity

Research has explored the use of Proverine in managing symptoms associated with Neurogenic Detrusor Overactivity (NDO). The evidence base here has an evidence level classified as moderate, relying on a smaller number of controlled trials supplemented by retrospective and prospective observational studies. In research scenarios where Proverine was evaluated in this specialized population, researchers monitored objective urodynamic endpoints, including bladder capacity and the pressure (or tension) of the bladder muscle.

---

Evidence Quality and Research Gaps

Research examined short-term changes in adult OAB symptoms. However, several research limitations exist that impact the certainty of the findings. The primary limitation is that follow-up durations were limited in the main controlled clinical trials, meaning that long-term effects are not fully established. Additionally, evidence quality varies across studies, especially for special populations like pediatric groups, where findings often rely on observational data with lower internal validity. The research provides context but not individual predictions, and it highlights what is known—and what is still uncertain—about Proverine.

Key Studies & References

1. A Review of its Use in the Treatment of Adults and Children with Overactive Bladder Associated with Idiopathic or Neurogenic Detrusor Overactivity

Common questions about Proverine (FAQ)

Q: What happens if I stop taking Proverine suddenly?

Clinical research has explored outcomes following the discontinuation of the medicine. Data suggests that the symptoms for which the medicine was prescribed may return or possibly worsen after stopping the treatment.

Q: Is Proverine suitable for patients with kidney problems?

Official product information describes specific restrictions for patients with kidney problems. For those with severe renal impairment, a maximum daily dose is established. All patients with kidney issues are generally subject to caution and observation during the use of this medicine.

Q: Is Proverine safe for someone with a history of liver issues?

The use of Proverine is generally not recommended in patients who have moderate or severe liver impairment. For those with mild liver impairment, the official documents state that the medicine should be used with caution and require careful observation.

Q: Has Proverine been studied for use in children or teenagers?

Regulatory documents indicate that Proverine is not established or indicated for use in the general pediatric population. This is due to a lack of established clinical data and sufficient evidence regarding the medicine’s effects in children and teenagers.

Q: Can Proverine affect my ability to drive or operate machinery?

The medicine may cause side effects that affect alertness, such as drowsiness, sleepiness, and blurred vision. Official guidance states that caution should be exercised when driving or operating heavy machinery until the effects of the medicine are understood.

Q: Can I drink alcohol while I am taking Proverine?

Official product information notes that caution is warranted when using this medicine alongside substances that depress the central nervous system. This is due to the potential for increased effects, and this category may include alcohol.

Q: How quickly should Proverine start to work after I begin taking it?

Clinical studies have examined the timeline for the medicine to begin working. Measurable changes in the symptoms for which the medicine is prescribed were typically assessed after a few weeks of consistent treatment, based on the research.

Q: Does Proverine cause drowsiness or make you tired?

Regulatory documents list fatigue and sleepiness as possible common side effects that have been reported with this medicine.

Q: Can Proverine affect my sleep pattern?

While changes to a person’s overall sleep pattern are not commonly listed as a side effect, official documents do note that the medicine can cause sleepiness. This potential effect may influence the quality or timing of rest.

Q: Is Proverine addictive or habit-forming?

Proverine is not classified as a controlled substance. This means it is not listed in the specialized regulatory databases designated for drugs with potential for misuse or dependence.

Q: How long does Proverine stay in your system after the last dose?

Pharmacokinetic data from official sources indicates that the medicine has a half-life of approximately 15 hours. The half-life describes the time it takes for the amount of medicine in the body to be reduced by half.

Q: Does Proverine cause weight gain or weight loss?

Regulatory documents list an increase in body weight as a Very Common adverse reaction that was observed in clinical data. Weight loss is not listed among the commonly reported side effects of this medicine.

Q: Can the effectiveness of Proverine decrease over time?

Research summaries indicate that the follow-up periods in the main clinical trials were limited. This means that long-term effects, including whether the medicine’s effectiveness might decrease over an extended period of time, are not fully established in the evidence base.

Q: Is it possible to be allergic to Proverine?

Official product information states that Proverine is contraindicated (must not be used) in persons with a known allergy or hypersensitivity to the active ingredient, propiverine hydrochloride, or any of the inactive components of the medicine.

Q: What does the term 'off-label use' mean for a drug like Proverine?

The term 'off-label use' is a regulatory description. It means that the medicine is being used for a purpose, a patient population, or a dosage that has not been specifically approved or listed in the official government-authorized product information for the drug.

Q: Does Proverine have any effect on blood pressure?

Official regulatory documents list a decrease in blood pressure as an uncommon side effect. This potential effect may be accompanied by drowsiness.

Q: Are there different formulations of Proverine (e.g., liquid, capsule)?

Regulatory documents describe Proverine as being available in solid oral dosage forms. These include film-coated tablets and modified-release capsules.

Q: Is Proverine used for short-term or long-term issues?

Research evidence focuses primarily on short-term changes in symptoms. Regulatory summaries note that long-term effects beyond the typical short-term monitoring periods are not fully established due to limitations in the follow-up durations of the main clinical trials.

Q: Are there different brand names for the same medicine as Proverine?

The active ingredient in Proverine, propiverine hydrochloride, is marketed under various brand names around the world. Examples include Mictonorm and Detrunorm.

Q: Why is the 45mg MR capsule not recommended for patients with severe renal impairment?

Official dosage guidelines establish a maximum daily dose of 30 mg for patients who have severe renal impairment, which is defined by specific measures of kidney function. The 45 mg dose is not recommended for this population to ensure adherence to this safety limit.

Storage and Disposal Requirements for Proverine (Propiverine hydrochloride)

Storage Conditions

Official regulatory documents mandate that Proverine must be stored at a temperature not exceeding 30°C and must be strictly protected from light and moisture. The product should not be refrigerated or frozen. To ensure product integrity, the medication must be stored in its original package, with the container kept tightly closed.

Child-Safety Storage

The medication must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Proverine must not be done via wastewater or household waste. The product must be discarded according to local pharmaceutical waste regulations and official protocols. This ensures that the contents do not contaminate the environment or enter sewers.